Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

868
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
868
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

868
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
868
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

245
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
245
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

359
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
359
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

542
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
542
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Assessing the concordance between ChatGPT-4 and EAU guidelines indications in bladder cancer management: a real-world study.

Minerva urology and nephrology·2026
Same author

Contemporary Practices in the Assessment and Management of Climacturia: Results from an International Survey.

European urology open science·2026
Same author

Performance of artificial intelligence chatbots compared with young academic urologists in reconstructive urology.

The French journal of urology·2026
Same author

Redefining clinical success in minimally invasive surgery for BPH: A composite endpoint integrating ejaculatory function, urinary improvement, and safety metrics.

Urologia·2026
Same author

Beyond surgery: the international masterclass in andrology and reconstructive surgery (iMARS) and the value of global collaboration in reconstructive urology and sexual medicine.

International journal of impotence research·2026
Same author

Urethral Complications After Masculinizing Genital Gender-affirming Surgery.

European urology focus·2026

関連する実験動画

Updated: Jan 13, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

785

孤立性食後性高脂血症と勃起不全の関連

Celeste Manfredi1, Giampiero Della Rosa1, Simone Tammaro1

  • 1Department of Woman, Child and General and Specialized Surgery, Unit of Urology, University of Campania "Luigi Vanvitelli", Naples, Italy.

Andrology
|January 10, 2026
PubMed
まとめ

孤立性食後性高脂血症（IPD）は、慢性高脂血症と同様に、勃起不全（ED）の有病率と重症度の増加と関連している。食後脂質検査は、性的健康に影響を与える代謝リスクを明らかにする可能性がある。

キーワード:
心血管代謝リスク勃起不全脂質プロファイル食後性高脂血症

さらに関連する動画

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.9K

関連する実験動画

Last Updated: Jan 13, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

785
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.9K

科学分野:

  • 心血管健康;代謝症候群;性医学

背景:

  • 食後脂質検査は、認識されている血管健康マーカーである。;食後性高脂血症と勃起不全（ED）の関連は十分に研究されていない。;孤立性食後性高脂血症（IPD）は、動脈硬化リスクがあるにもかかわらず、空腹時検査で見逃される可能性がある。

研究 の 目的:

  • IPDと勃起機能の関連を調査する。;IPD、混合性高脂血症（CD）、および高脂血症のない（WD）男性におけるEDの有病率と重症度を比較する。

主な方法:

  • 18歳以上の男性351名を対象とした横断研究。;同日の空腹時および食後脂質検査と勃起機能に関するIIEF-EF質問票の実施。;高脂血症基準に基づくWD、IPD、CD群への分類。多変量ロジスティック回帰分析。

主要な成果:

  • EDの有病率は、IPD（55.1%）およびCD（57.0%）群でWD（32.8%）群よりも有意に高かった。;中央値IIEF-EFスコアは、IPDおよびCD群でWD群と比較して低く、統計的に有意かつ臨床的に意味のある差が見られた。;調整後解析では、WD群と比較してIPDおよびCD群でEDのオッズが増加することが示された。;EDの重症度も高かった。

結論:

  • IPDは、慢性高脂血症と同様に、EDの有病率と重症度の両方に関連している。;食後脂質検査は、性的健康に関連する代謝リスクを特定できる。;ED評価における食後脂質検査の考慮が推奨される。